IPCA LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,218 INR | -0.77% |
|
+2.36% | +9.40% |
| Sales 2024 | 77.05B 923M | Sales 2025 * | 90.62B 1.09B | Capitalization | 311B 3.72B |
|---|---|---|---|---|---|
| Net income 2024 | 5.47B 65.54M | Net income 2025 * | 9.05B 108M | EV / Sales 2024 | 4.22 x |
| Net Debt 2024 | 11.42B 137M | Net Debt 2025 * | 8.75B 105M | EV / Sales 2025 * | 3.52 x |
| P/E ratio 2024 |
57.4
x | P/E ratio 2025 * |
34
x | Employees | 16,167 |
| Yield 2024 * |
0.4% | Yield 2025 * |
0.44% | Free-Float | 52.27% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ipca Laboratories Limited
More recommendations
| 1 day | -0.77% | ||
| 1 week | +2.36% | ||
| Current month | +7.39% | ||
| 1 month | +2.99% | ||
| 3 months | -8.23% | ||
| 6 months | +6.80% | ||
| Current year | +9.40% |
1 week
1 197.60
1 241.50
1 month
1 060.951 241.50
Current year
1 058.701 373.95
1 year
765.051 373.95
3 years
670.001 383.55
5 years
422.101 383.55
10 years
200.001 383.55
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 68 | 80-04-01 | |
Pranay Godha
CEO | Chief Executive Officer | 51 | 03-04-15 |
| Chairman | 77 | 75-10-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 77 | 75-10-30 | |
| Director/Board Member | 76 | 11-08-15 | |
Pranay Godha
CEO | Chief Executive Officer | 51 | 03-04-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-16 | 1,218 | -0.77% | 8 399 |
| 24-07-15 | 1,227 | +0.36% | 7,667 |
| 24-07-12 | 1,223 | -0.07% | 18,889 |
| 24-07-11 | 1,224 | -0.10% | 9,875 |
| 24-07-10 | 1,225 | +0.32% | 45,071 |
Delayed Quote Bombay S.E., July 16, 2024 at 06:00 am EDT
More quotes
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIâs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Pharma Nigeria Ltd., Trophic Wellness Pvt. Ltd.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
18
Last Close Price
1,218
INR
Average target price
1,216
INR
Spread / Average Target
-0.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +62.02% | 856B | |
| +38.95% | 631B | |
| -4.16% | 359B | |
| +15.53% | 325B | |
| +9.20% | 297B | |
| +5.89% | 234B | |
| +16.53% | 226B | |
| +16.06% | 177B | |
| +2.39% | 165B |
- Stock Market
- Equities
- IPCALAB Stock
- IPCALAB Stock
